Abstract
Background: COPD impairs the physiological and structural function of the lungs and negatively impacts physical performance. Patients with emphysema typically have significant impairments in daily activities and a reduced quality of life.
Objective: We assessed health-related quality of life at the 24-month followup in patients with severe heterogeneous emphysema treated with the Spiration Valve System (SVS) versus optimal medical managment (Control) in EMPROVE.
Methods: EMPROVE was a prospective, mulitcenter, randomized controlled trial. Patients were randomized in a 2:1 allocation to SVS treatment (n=97) or Control (n=44). Disease-targeted measures of health-related quality of life were determined using the St. George's Respiratory Questionnaire (SGRQ), the modified Medical Research Council dyspnea scale (mMRC) and the COPD Assessment Test (CAT) at 1, 3, 6,12 and 24 months.
Results: The SVS-treated group demosntrated significant improvements in SGRQ (p=0.037) at 24 months with a mean change of -6.5 points, with a similar improvement in CAT (−2.6 points for the SVS treatment and Control groups, respectively, p=0.048). Dyspena also improved post SVS treament compared to the Control group with a mean reduction of -0.6 points in the mMRC Dyspena Scale, yielding a significant difference between groups (p=0.0012).
Conclusion: Our results from the EMPROVE trial demonstrate that SVS treatment provides a sustained clinically significant benefit in health-related quality of life in patients with severe heterogeneous emphysema.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4446.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
